Expesicor Overview

  • Year Founded
  • 2016

Year Founded

  • Status
  • Out of Business

  • Employees
  • 3

Employees

  • Latest Deal Type
  • Out of Business

Expesicor General Information

Description

Developer of therapeutics, imaging probes, and drug screening tools designed to prevent, treat, and cure neurological disorders. The company's novel positron emission tomography imaging agent assists in the visualization and objective measurement of pain, enabling healthcare providers to treat neurological maladies, including epilepsy, traumatic brain injury, and neurodegenerative disorders.

Contact Information

Ownership Status
Out of Business
Financing Status
Formerly VC-backed
Corporate Office
  • 1121 East Broadway Street
  • Missoula, MT 59802
  • United States
+1 (520)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • 1121 East Broadway Street
  • Missoula, MT 59802
  • United States
+1 (520)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Expesicor Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
8. Out of Business 09-May-2026 Completed Out of Business
7. Secondary Transaction - Private Completed Pre-Clinical Trials
6. Accelerator/Incubator Completed Pre-Clinical Trials
5. Seed Round 01-Sep-2020 Completed Pre-Clinical Trials
4. Grant 07-Nov-2019 Completed Startup
3. Grant 09-Sep-2019 Completed Startup
2. Seed Round 31-Jan-2019 $1.1M $1.1M Completed Startup
1. Grant 25-Jul-2017 $101K Completed Startup
To view Expesicor’s complete valuation and funding history, request access »

Expesicor Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Seed 2b
Seed 2a
Seed 1 494,382 $0.000001 $2.23 $2.23 1x $2.23 11.12%
To view Expesicor’s complete cap table history, request access »

Expesicor Patents

Expesicor Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2017386526-A1 A non-human animal model of neurodegenerative disorders Active 28-Dec-2016
AU-2017386526-B2 A non-human animal model of neurodegenerative disorders Inactive 28-Dec-2016
CA-3048633-A1 A non-human animal model of neurodegenerative disorders Inactive 28-Dec-2016
EP-3562553-A1 A non-human animal model of neurodegenerative disorders Inactive 28-Dec-2016
EP-3562553-A4 A non-human animal model of neurodegenerative disorders Inactive 28-Dec-2016 A01K67/027
To view Expesicor’s complete patent history, request access »

Expesicor Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Expesicor FAQs

  • When was Expesicor founded?

    Expesicor was founded in 2016.

  • Where is Expesicor headquartered?

    Expesicor is headquartered in Missoula, MT.

  • What is the size of Expesicor?

    Expesicor has 3 total employees.

  • What industry is Expesicor in?

    Expesicor’s primary industry is Drug Discovery.

  • Is Expesicor a private or public company?

    Expesicor is a Private company.

  • What is Expesicor’s current revenue?

    The current revenue for Expesicor is .

  • How much funding has Expesicor raised over time?

    Expesicor has raised $3.1M.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process